Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 216

1.

Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1.

Autiero M, Waltenberger J, Communi D, Kranz A, Moons L, Lambrechts D, Kroll J, Plaisance S, De Mol M, Bono F, Kliche S, Fellbrich G, Ballmer-Hofer K, Maglione D, Mayr-Beyrle U, Dewerchin M, Dombrowski S, Stanimirovic D, Van Hummelen P, Dehio C, Hicklin DJ, Persico G, Herbert JM, Communi D, Shibuya M, Collen D, Conway EM, Carmeliet P.

Nat Med. 2003 Jul;9(7):936-43.

PMID:
12796773
2.

Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1.

Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, Liao F, Nagy JA, Hooper A, Priller J, De Klerck B, Compernolle V, Daci E, Bohlen P, Dewerchin M, Herbert JM, Fava R, Matthys P, Carmeliet G, Collen D, Dvorak HF, Hicklin DJ, Carmeliet P.

Nat Med. 2002 Aug;8(8):831-40.

PMID:
12091877
3.

Heterodimers of placenta growth factor/vascular endothelial growth factor. Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR.

Cao Y, Chen H, Zhou L, Chiang MK, Anand-Apte B, Weatherbee JA, Wang Y, Fang F, Flanagan JG, Tsang ML.

J Biol Chem. 1996 Feb 9;271(6):3154-62.

4.

Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis.

Liu ZJ, Shirakawa T, Li Y, Soma A, Oka M, Dotto GP, Fairman RM, Velazquez OC, Herlyn M.

Mol Cell Biol. 2003 Jan;23(1):14-25.

5.

Novel role of gp91(phox)-containing NAD(P)H oxidase in vascular endothelial growth factor-induced signaling and angiogenesis.

Ushio-Fukai M, Tang Y, Fukai T, Dikalov SI, Ma Y, Fujimoto M, Quinn MT, Pagano PJ, Johnson C, Alexander RW.

Circ Res. 2002 Dec 13;91(12):1160-7. Retraction in: Circ Res. 2014 Jan 17;114(2):e22.

6.

VEGFR-1-selective VEGF homologue PlGF is arteriogenic: evidence for a monocyte-mediated mechanism.

Pipp F, Heil M, Issbrücker K, Ziegelhoeffer T, Martin S, van den Heuvel J, Weich H, Fernandez B, Golomb G, Carmeliet P, Schaper W, Clauss M.

Circ Res. 2003 Mar 7;92(4):378-85.

7.

Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization.

Rakic JM, Lambert V, Devy L, Luttun A, Carmeliet P, Claes C, Nguyen L, Foidart JM, Noël A, Munaut C.

Invest Ophthalmol Vis Sci. 2003 Jul;44(7):3186-93.

PMID:
12824270
8.

Angiogenesis-independent endothelial protection of liver: role of VEGFR-1.

LeCouter J, Moritz DR, Li B, Phillips GL, Liang XH, Gerber HP, Hillan KJ, Ferrara N.

Science. 2003 Feb 7;299(5608):890-3.

9.

Upregulation of the angiogenic factors PlGF, VEGF and their receptors (Flt-1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization.

Viglietto G, Romano A, Manzo G, Chiappetta G, Paoletti I, Califano D, Galati MG, Mauriello V, Bruni P, Lago CT, Fusco A, Persico MG.

Oncogene. 1997 Nov 27;15(22):2687-98.

10.
12.

Autocrine-paracrine VEGF loops potentiate the maturation of megakaryocytic precursors through Flt1 receptor.

Casella I, Feccia T, Chelucci C, Samoggia P, Castelli G, Guerriero R, Parolini I, Petrucci E, Pelosi E, Morsilli O, Gabbianelli M, Testa U, Peschle C.

Blood. 2003 Feb 15;101(4):1316-23.

13.
15.

HGF/NK4 inhibited VEGF-induced angiogenesis in in vitro cultured endothelial cells and in vivo rabbit model.

Nakabayashi M, Morishita R, Nakagami H, Kuba K, Matsumoto K, Nakamura T, Tano Y, Kaneda Y.

Diabetologia. 2003 Jan;46(1):115-23.

PMID:
12637990
16.

Analysis of a zebrafish VEGF receptor mutant reveals specific disruption of angiogenesis.

Habeck H, Odenthal J, Walderich B, Maischein H, Schulte-Merker S; Tübingen 2000 screen consortium..

Curr Biol. 2002 Aug 20;12(16):1405-12.

17.
18.

Vascular endothelial growth factor and signaling in the prostate: more than angiogenesis.

Chevalier S, Defoy I, Lacoste J, Hamel L, Guy L, Bégin LR, Aprikian AG.

Mol Cell Endocrinol. 2002 Mar 28;189(1-2):169-79.

PMID:
12039075
19.

Endothelial nitric oxide synthase is strongly expressed in malignant mesothelioma but does not associate with vascular density or the expression of VEGF, FLK1 or FLT1.

Soini Y, Puhakka A, Kahlos K, Säily M, Pääkkö P, Koistinen P, Kinnula V.

Histopathology. 2001 Aug;39(2):179-86.

PMID:
11493335

Supplemental Content

Support Center